By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Adynxx, Inc. (ADYX)

OTC Currency in USD
$0.00
$0.00
0.00%
Last Update: 29 Aug 2025, 00:00
$581.00
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
$0.00 - $0.00
52 Week Range

ADYX Stock Price Chart

Explore Adynxx, Inc. interactive price chart. Choose custom timeframes to analyze ADYX price movements and trends.

ADYX Company Profile

Discover essential business fundamentals and corporate details for Adynxx, Inc. (ADYX) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

18 Dec 1998

Employees

6.00

CEO

Richard Orr

Description

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

ADYX Financial Timeline

Browse a chronological timeline of Adynxx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

No results found.

ADYX Stock Performance

Access detailed ADYX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run